New combo therapy aims to tame AML without harsh chemo
NCT ID NCT07014462
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 31 times
Summary
This study tests whether adding the anti-inflammatory drug dexamethasone to a standard low-intensity therapy (venetoclax plus another chemo drug) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 20 participants will receive the combination over six cycles. The main goal is to check for side effects, with secondary goals of tracking quality of life and treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML - ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Conditions
Explore the condition pages connected to this study.